• BCWorldPharm announced a 2026 value-enhancement plan on October 16, targeting a medium- to long-term price-to-book ratio of 1.
• The plan targets positive return on equity in the short term, rising to 10% over the medium to long term.
• A return to profitability would restore a calculable price-to-earnings ratio; sales growth and cost improvements would support higher net margins.
• Expanded investor relations, research and development, and new product introductions aim to strengthen growth expectations.
• A higher dividend payout ratio is planned, while more efficient inventory management would improve total asset turnover.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BCWorldPharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261019900252), on October 19, 2026, and is solely responsible for the information contained therein.